Arrowhead Pharmaceuticals (ARWR) Research & Development (2016 - 2025)
Historic Research & Development for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $177.2 million.
- Arrowhead Pharmaceuticals' Research & Development rose 2934.34% to $177.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $647.4 million, marking a year-over-year increase of 2298.32%. This contributed to the annual value of $607.2 million for FY2025, which is 2002.27% up from last year.
- According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Research & Development is $177.2 million, which was up 2934.34% from $174.7 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' Research & Development's 5-year high stood at $177.2 million during Q4 2025, with a 5-year trough of $44.7 million in Q1 2021.
- Its 5-year average for Research & Development is $105.5 million, with a median of $97.3 million in 2023.
- In the last 5 years, Arrowhead Pharmaceuticals' Research & Development soared by 8212.94% in 2021 and then tumbled by 145.29% in 2023.
- Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Research & Development stood at $65.8 million in 2021, then grew by 27.26% to $83.7 million in 2022, then surged by 39.19% to $116.5 million in 2023, then rose by 17.61% to $137.0 million in 2024, then increased by 29.34% to $177.2 million in 2025.
- Its Research & Development was $177.2 million in Q4 2025, compared to $174.7 million in Q3 2025 and $162.4 million in Q2 2025.